Is French Firm Ethypharm's Sudden India Exit Part Of Larger Consolidation?
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The recently announced India exit of French oral drug delivery specialist Ethypharm marks the end of a 13-year long journey that started with lofty ambitions but perhaps lacked patience in tailoring management strategies to adjust with the realities of doing business in India, experts said
You may also be interested in...
Piramal Healthcare Chairman Ajay Piramal On Meeting The World's Need For High Quality Delivered At Low Cost: An Interview With PharmAsia News (Part 1 of 2)
Ajay Piramal, chairman of the $550 million Piramal Healthcare and Piramal Lifesciences, has brought up his company in the last 20 years, working ceaselessly on signing marketing arrangements with multinational companies for the Indian market, strategic buyouts both in India and abroad, carving out contract manufacturing and then establishing a discovery research entity. Known as the takeover tycoon in Indian corporate circles, Piramal has closed important deals with top-notch global companies like Pfizer. From inheriting a fledgling textiles business in the 1980s to putting together a strong pharmaceutical business from scratch, Ajay Piramal sat down with PharmAsia News' India Bureau to share his vision for the company.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).